Lincoln, NE – June 11, 2021 – Adjuvance Technologies Inc. announced today that it has been selected to deliver a company presentation at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled June 10-11 & 14-18, 2021.
J. Tyler Martin MD, CEO and President will present an update on the semi-synthetic saponin adjuvant TQL-1055 that is being evaluated in first-in-human clinical trial. The presentation will be available to registered attendees at 9 am ET June 10.
About TQL-1055: TQL-1055 is a rationally designed, semi-synthetic analogue of the saponin adjuvant QS-21. The molecule structure and synthesis are designed for manufacturing efficiency. The natural source material in TQL-1055 that provides the triterpene core is sustainably harvested from the Quillaja saponaria tree. Preclinical evidence indicates that TQL-1055 will have immunostimulatory properties similar to QS21, with improved tolerability. TQL-1055 is in clinical development and multiple indications are being pursued in infectious disease, oncology and others.
About Adjuvance Technologies
Adjuvance Technologies is a privately held biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in vaccine adjuvant design and manufacturing. Adjuvants are critical components that improve the immune response of
many vaccines. Adjuvance Technologies has developed the ability to synthesize nextgeneration saponin adjuvants such as those used in shingles, malaria, flu and COVID-19 vaccines.
Headquartered in Lincoln, Nebraska, Adjuvance is a partner of the Nebraska Innovation Campus. The company has received grant funding from the National Institute of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and
BIO is the world’s largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The BIO International Convention is the world’s largest gathering of the biotechnology industry. Subscribe to Good Day BIO.